Fullana, M. Neus
Ferrés-Coy, Albert
Ortega, Jorge E.
Ruiz-Bronchal, Esther
Paz, Verónica
Meana, J. Javier
Artigas, Francesc
Bortolozzi, Analia http://orcid.org/0000-0002-2069-9192
Funding for this research was provided by:
National Alliance for Research on Schizophrenia and Depression (20003)
Secretaría de Estado de Investigación, Desarrollo e Innovación (SAF2016-75797-R, SAF2013-48586-R)
Consejo Superior de Investigaciones Científicas (SAF2015-68346-P)
Article History
Received: 5 April 2018
Accepted: 30 July 2018
First Online: 7 August 2018
Compliance with Ethical Standards
:
: F.A. has received consulting honoraria on antidepressant drugs from Lundbeck and he has been PI of grants from Lundbeck. A.B. has been PI of grants from Nlife Therapeutics. S.L., F.A., and A.B. are coauthors of the patent WO/2011/131693 for the siRNA and ASO (antisense oligonucleotides) molecules and the targeting approach related to this work. The rest of authors declare no competing financial interest.